Medline ® Abstract for Reference 4
of 'Clinical features and diagnosis of restless legs syndrome/Willis-Ekbom disease and periodic limb movement disorder in adults'
4
TI
Refining duration and frequency thresholds of restless legs syndrome diagnosis criteria.
AU
Ohayon MM, Bagai K, Roberts LW, Walters AS, Milesi C
SO
Neurology. 2016 Dec;87(24):2546-2553.
OBJECTIVE:
This study assesses the prevalence of restless legs syndrome (RLS) using DSM-5 criteria and determines what is the most appropriate threshold for the frequency and duration of RLS symptoms.
METHODS:
The Sleep-EVAL knowledge base system queried the interviewed subjects on life, sleeping habits, and health. Questions on sleep and mental and organic disorders (DSM-5, ICD-10) were also asked. A representative sample of 19,136 noninstitutionalized individuals older than 18 years living in the United States was interviewed through a cross-sectional telephone survey. The participation rate was 83.2%.
RESULTS:
The prevalence of the 4 leg symptoms describing RLS occurring at least 1 d/wk varied between 5.7% and 12.3%. When the frequency was set to at least 3 d/wk, the prevalence dropped and varied between 1.8% and 4.5% for the 4 leg symptoms. Higher frequency of leg symptoms was associated with greater distress and impairment with a marked increase at 3 d/wk. Symptoms were mostly chronic, lasting for more than 3 months in about 97% of the cases. The prevalence of RLS according to DSM-5 was 1.6% (95% confidence interval 1.4%-1.8%) when frequency was set at 3 d/wk. Stricter criteria for frequency of restless legs symptoms resulted in a reduction of prevalence of the disorder. The prevalence was further reduced when clinical impact was taken into consideration.
CONCLUSIONS:
In order to avoid inflation of case rates and to identify patients in whom treatment is truly warranted, using a more conservative threshold of 3 times or greater per week appears the most appropriate.
AD
From the Division of Public Mental Health&Population Sciences, Stanford Sleep Epidemiology Research Center (M.M.O.), and Department of Psychiatry and Behavioral Sciences (L.W.R.), Stanford University, School of Medicine, Palo Alto, CA; the Department of Neurology, Division of Sleep Medicine (K.B., A.S.W.), Vanderbilt University Medical Center, Nashville, TN; and the Institute of Public Health&Environment (C.M.), Palo Alto, CA. mohayon@stanford.edu.
PMID
